|
Latent autoimmune hepatitis triggered during interferon
therapy in patients with chronic Hepatitis C
L Garcia-Buey, C Garcia-Monzon, S Rodriguez, MJ Borque, A Garcia-Sanchez, R
Iglesias, M DeCastro, FG Mateos, JL Vicario and A Balas
Liver Unit, Hospital de la Princesa, Universidad Autonoma de Madrid, Spain.
BACKGROUND/AIMS:
Interferon can induce autoantibodies and autoimmune reactions. This study reviewed
the clinical, serological, and HLA phenotypical features of patients who developed
autoimmune hepatitis during interferon therapy for chronic Hepatitis C, analyzing
their response to immunosuppressive treatment.
METHODS:
The diagnosis of chronic Hepatitis C was based on positivity for viral RNA
and a liver biopsy specimen obtained before interferon treatment. Sera were
tested for autoantibodies by indirect immunofluorescence assay. HLA typing was
performed by applying a standard microlymphocytotoxicity method.
RESULTS:
Of 144 patients with chronic Hepatitis C treated with interferon, 7 women deteriorated
during treatment; serum transaminase, gamma-globulin, and immunoglobulin G levels
increased; and serum autoantibodies became positive. Interferon was interrupted,
a diagnosis of autoimmune hepatitis was established, and immunosuppressive therapy
was initiated. All patients responded to this treatment. The 7 patients had
similar HLA typing to those with autoimmune hepatitis, with DR4 in 2 patients
(67%) with type 2 autoimmune hepatitis, and with DR3 and DR52 in 2 (50%) and
4 (100%) patients, respectively, with type 1 autoimmune hepatitis; additionally,
5 patients (71%) had DQ2, and 4 (57%) had both DR52 and DQ2.
CONCLUSIONS:
In female patients with chronic Hepatitis C, a genetic susceptibility to autoimmune
hepatitis may exist, possibly triggered by immunostimulating effects during
interferon therapy. Immunosuppressive treatment has been well tolerated and
seems to be effective.
Gastroenterology, Vol 108, 1770-1777,
Copyright © 1995 by American Gastroenterological Association
|